Connect with us

Technology

Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™

Published

on

DELRAY BEACH, Fla., Nov. 12, 2024 /PRNewswire/ — The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 billion in 2024, at a CAGR of 29.9% from 2024  to 2029. The rising shift towards integrating AI for understanding diseases and small molecule design and optimization use cases augments the growth of the market. AI tools play a major role in accelerating target identification, optimizing lead compound selection, and predicting drug efficacy and toxicity. Supervised methods such as regression, decision trees, and neural networks help predict material properties and drug candidate profiles. In contrast, unsupervised techniques such as clustering algorithms (k-means and hierarchical clustering) and dimensionality reduction identify hidden trends, patterns, and groupings in data, aiding in novel drug discovery. Deep Learning is employed to predict molecular properties, design new compounds, and other applications. Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs) are more commonly used for handling complex data, such as sequences or molecular structures. Generative Adversarial Networks (GANs) are utilized to generate de novo or novel drug candidates, molecular structure simulation, and lead optimization. These tools help streamline processes, as well as reduce the time and cost involved in screening, optimizing, and discovering new drug candidates.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446

Browse in-depth TOC on “Artificial Intelligence in Drug Discovery Market”

270 – Tables
50 – Figures
350 – Pages

Based on therapeutic area, the artificial intelligence (AI) in drug discovery market is segmented into oncology, infectious diseases, neurology, metabolic diseases, cardiovascular diseases, immunology, mental health, and others (respiratory diseases, nephrology, dermatological diseases, genetic disorders, inflammatory diseases, and gastrointestinal). The neurology segment held the fastest market share in the Al drug discovery market due to the increasing number of neurological disorders and the difficulties associated with drug discovery in this field, The use of Al technologies accelerates drug development because neurological diseases such as Parkinson’s, Alzheimer’s, and multiple sclerosis are difficult to diagnose and treat.

According to the WHO, in 2021, neurological conditions affected over 3 billion people worldwide. This emphasizes the need for innovative healthcare solutions. Al-powered drug discovery platforms work well in neurology, allowing faster and more accurate analysis of complex neurological data to identify potential drug candidates. The increasing availability of large datasets from clinical trials, genomics, neuroimaging, and electronic health records (EHR) records, as well as the growth investments in neurology, also contribute to market growth. In 2023, venture investments in neurology companies were USD 1.14 billion in the US. Resources like the Alzheimer’s Disease Neuroimaging Initiative (ADNI) provide vast data for machine learning applications.

Based on the process, artificial intelligence (AI) in drug discovery market is broadly classified into target identification & selection, target validation, hit identification & prioritization, hit-to-lead identification/lead generation, lead optimization, and candidate selection & validation. Hit-to-lead identification/lead generation accounts for the largest process segment in this market; it is also expected to register the highest growth owing to its critical role in streamlining the early stages of the drug development process. AI can significantly reduce the number of compounds and experiments required to find and optimize leads. This procedure uses Al algorithms to analyse large datasets, such as chemical libraries and biological interactions, to identify potential drug candidates or hits and develop them into viable leads. AI helps address long design-make-test cycles across discovery journeys. Faster screening and better exploration of vast chemical libraries are fuelling market growth for AI solutions for hit-to-lead identification/lead generation. For example, activity prediction enables more targeted experiments, and predictive analytics can help forecast compound properties. However, the lack of existing clinical data for a new molecule can hinder market growth.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446

There are several opportunities in AI in drug discovery market such as growing biotech industry, emerging markets, AI in single cell experiments, Growing demand for precision medicine and personalized medicine. Key players in the artificial intelligence (AI) in drug discovery are NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Valo Health (US) among others. These players not only have a comprehensive and diverse product portfolio but also a strong geographic presence.

The key players in this market can tap these opportunities to enhance and improve their product offerings and develop innovative AI solutions for various processes, use cases, and end users. Moreover, these companies can integrate AI in drug design and optimization, understanding diseases, drug repurposing, single-cell analysis, and identification of biomarkers, disease types, and subtypes. Additionally, key players invest in AI algorithms that can examine complicated data and interpret disease mechanisms and pathways. Collaborations and partnerships between key players continue to grow rapidly, which in turn has accelerated the development of targeted therapies and contributed to rapidly expanding drug pipelines.

These market players have offered a diverse range of products and services and have operations worldwide with a major focus on North America. They rely on technological advancements to avail themselves of innovative end-to-end solutions, software, and services and increase their global footprint. These players focus on product launches and enhancements, investments, partnerships, collaborations, agreements, joint ventures, funding, acquisitions, expansions, conferences, FDA clearances, sales contracts, alliances, and other recent developments to expand their global reach and develop AI in drug discovery solutions.

NVIDIA Corporation:

NVIDIA Corporation, a prominent technology company, has made remarkable advances in artificial intelligence (AI), particularly drug discovery. NVIDIA GPUs power AI workloads in drug discovery applications such as molecular modeling, simulation, and machine learning. Nvidia’s AI software includes development tools, libraries, and frameworks that can be used to build and deploy AI applications for drug discovery. The company provides generative AI platforms like BioNeMo and Clara Discovery. NVIDIA BioNeMo simplifies the deployment of AI models, hastening the transition to AI-driven drug discovery. It offers models for 3D protein structure prediction, molecule generation, property predictions, and molecular docking. Users can customize AI models with their data, access pre-trained models, and integrate them into drug discovery workflows. NVIDIA Clara Discovery is a software suite that includes a variety of tools for AI-driven drug discovery.

NVIDIA Corporation operates more than 50 offices across the Americas, Asia, and Europe, along with manufacturing facilities in the US and Taiwan. The company collaborates with several pharmaceutical companies and biotech startups to develop solutions for AI-driven drug discovery. For example, in November 2023, NVIDIA collaborated with Genentech to improve computational models and incorporate generative AI into drug discovery processes, allowing for faster exploration of molecular designs.

Insilico Medicine:

Insilico Medicine is an end-to-end generative AI-driven biotech company accelerating drug discovery and development to treat cancer and age-related diseases. Its proprietary Pharma.AI platform spans biology, chemistry, and clinical development. The company pioneered the application of reinforcement learning and generative adversarial networks (GANs) to develop new molecular structures for diseases with known and unknown targets. Its products and services are used by pharmaceutical companies, biotechnology companies, and academic research institutions. Insilico Medicine has produced a diversified internal pipeline of 31 programs for 29 drug targets. The company’s lead drug is ISM001-055, a small-molecule chemical drug candidate primarily designed to treat fibrosis-related indications, including idiopathic pulmonary fibrosis. The company has offices in the US, Hong Kong, Canada, and the UAE. The company has more than 150 academic and industrial collaborations worldwide. For instance, in September 2024, Insilico Medicine collaborated with Inimmune to leverage its proprietary AI platform, Chemistry42, in accelerating the discovery and development of next generation immunotherapeutic.

Exscientia:

Exscientia is an AI-driven small-molecule drug discovery and design company. The company designed and developed an end-to-end solution of AI and experimental technologies for target identification, drug candidate design, translational models, and patient selection. The company’s patient-first AI process comprises four elements, namely, Precision Target (experimental and literature-based AI systems to prioritize projects), Precision Design (an extensive platform of AI technologies to design innovative drugs), Precision Experiment (tech-enabled precision experimentation to derive better data), and Precision Medicine (integrated analysis of patient data to ensure clinical relevance). The platform has helped design candidate drug molecules that have progressed into clinical trials and improve disease understanding through AI-guided assessment and generative AI. Exscientia collaborates with pharmaceutical companies such as GSK, Sanofi, and Roche. The company has offices in the UK, the US, and Japan. For instance, in July 2024, Exscientia announced the expansion of its collaboration with Amazon Web Services, Inc. to utilize AWS’s AI and machine learning services, further enhancing its end-to-end drug discovery and automation platform.

For more information, Inquire Now!

Related Reports:

Microscopy Market

Synthetic Biology Market

Metagenomic Sequencing Market

Proteomics Market

Digital Pathology Market

Get access to the latest updates on Artificial Intelligence in Drug Discovery Companies and Artificial Intelligence in Drug Discovery Market Size

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-in-drug-discovery-market-to-hit-usd-6-89-billion-by-2029-with-29-9-cagr–marketsandmarkets-302302221.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ERCO Seoul Unveils State-of-the-Art Experience Centre

Published

on

By

ERCO’s new Experience Centre in Seoul invites industry professionals to experience the future of lighting design. This immersive space offers exclusive workshops, demonstrations, and insights into the latest trends, showcasing ERCO’s commitment to elevating architectural projects.

SEOUL, South Korea, Nov. 14, 2024 /PRNewswire/ — ERCO, a global leader in architectural lighting, is excited to announce the relocation of its Seoul office to a modern, state-of-the-art facility. This move reflects ERCO’s dedication to providing exceptional service and innovative lighting solutions to its valued customers in South Korea.

The new office, located at #103, 33, Dosan-daero 27-gil, Gangnam-gu, Seoul 06032, offers enhanced accessibility and convenience for customers and partners. This strategic relocation underscores ERCO’s commitment to expanding its presence and supporting the growing demand for architectural lighting in the region.

A highlight of the new office is the immersive ERCO Experience Centre. This innovative space showcases ERCO’s latest lighting technologies and solutions. Visitors can witness firsthand how ERCO’s lighting systems seamlessly integrate with architecture to create stunning and functional spaces. The Experience Centre is an inspiring hub for architects, designers, and lighting professionals to explore the possibilities of ERCO’s lighting, gain inspiration for their projects, and foster creative collaboration.

Lim Chul-Hoon, Branch Manager of ERCO Seoul, “We’re thrilled to unveil the new ERCO Experience Centre in Seoul. This relocation allows us to provide an even better experience for our clients. The Centre is a space where they can truly experience the transformative power of ERCO’s lighting solutions and how they can elevate their architectural designs.”

Jack Tan, Asia Pacific Managing Director at ERCO, added, “The relocation and Experience Centre demonstrate ERCO’s ongoing commitment to pushing boundaries and exceeding customer expectations across the region. This state-of-the-art facility showcases our dedication to providing industry-leading lighting solutions. We’re excited to welcome our clients for an immersive experience of ERCO’s capabilities.”

Architects, designers, and lighting professionals interested in attending a lighting workshop or exploring the Experience Centre can contact ERCO Seoul at +82 2 596 3366 or info.kr@erco.com.

About ERCO

ERCO is a global leader in high-quality, digital architectural lighting. Founded in 1934, this family-owned company operates in 55 countries with independent sales organizations and partners.

ERCO views light as the fourth dimension of architecture, thus an essential element of sustainable architecture. By contributing to better societies and buildings while preserving the environment, ERCO Greenology® combines ecological responsibility with technological innovation.

ERCO develops, designs, and manufactures luminaires at its light factory in Lüdenscheid, Germany. Focusing on photometric optics, electronics, and sustainable design, ERCO’s products are used in a variety of applications, including: Work and Culture, Community and Public/Outdoor, Contemplation, Living, Shop and Hospitality.

ERCO lighting experts collaborate with architects and designers worldwide to create highly precise, efficient, and sustainable lighting solutions that bring projects to life.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/erco-seoul-unveils-state-of-the-art-experience-centre-302286861.html

SOURCE ERCO Lighting

Continue Reading

Technology

Suvoda Awarded US Patent for its eCOA Software Architecture

Published

on

By

Low-code, no-code approach accelerates eCOA questionnaire design and deployment, taking questionnaire creation, licensing, and localization off the critical path 

PHILADELPHIA, Nov. 14, 2024 /PRNewswire/ — Suvoda, a global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases, announced the receipt of a patent from the US Patent Office for the Suvoda Questionnaire Definition Language (SQDL), part of the software architecture of its eCOA (electronic Clinical Outcome Assessment) product. 

The patent demonstrates the power of Suvoda eCOA: expedited questionnaire creation, translation, localization, and deployment so clinical trial sponsors can launch their studies more efficiently. While eCOA is traditionally a bottleneck in clinical trial implementation, Suvoda eCOA and its SQDL tool enable sponsors to deliver high quality questionnaires in a matter of hours, instead of days.  

“This recognition by the US Patent Office is a testament to the ingenuity, creativity, and technical excellence of our team. Many claim to offer similar capabilities, but Suvoda’s patented technology enables us to truly deliver on our promises. Suvoda eCOA accelerates questionnaire implementation in a regulatory compliant manner, which is crucial for the efficiency and success of clinical trials,” said Jagath Wanninayake, CEO of Suvoda. 

The patented architecture offers several key benefits: 

Easy eCOA questionnaire creation: Suvoda eCOA allows non-engineers to define eCOA questionnaires using a simple low-code/no-code approach, while maintaining rigorous regulatory compliance. It includes a real-time preview of each question, language, and layout configuration to improve feedback and productivity.

Accelerate development by parallel processing: Questionnaire definition, licensing, translation, and layout occur concurrently and are decoupled from the study build.

Localization partners work directly in Suvoda eCOA, previewing translations in real-time and minimizing back-and-forth with Suvoda and the sponsor. 

Simplified mid-study questionnaire updates: Questionnaires can be easily modified while maintaining the validated state of the eCOA system, so that mid-study changes do not delay data collection.

Efficient questionnaire and component reuse: Suvoda eCOA allows questionnaires, where permitted, to be stored and reused in an accessible and organized way and allows for compatibility with newly updated devices without affecting system validation. 

“The SQDL architecture fundamentally changes how eCOA questionnaires are created by supporting parallel construction of translations and layouts. We have patented the core of what we do, supporting a powerful no-code/low-code definition layer that enables an ecosystem of tools—like real-time, device-accurate previews and screenshot generation—that can improve eCOA implementation and deployment,” explained Andrew McVeigh, Suvoda’s Chief Architect. 

Suvoda eCOA is part of a comprehensive suite of clinical trial solutions, including IRT (Interactive Response Technology), eConsent, and the recently launched ePatient. Unified on the purpose-built Suvoda technology platform, these products support clinical trial sponsors in the most urgent moments of their studies, enabling them to enhance operational efficiency, reduce site-burden, transform patients’ trial journeys, and help advance human health. 

For more information about Suvoda and its innovative eCOA solution, visit https://www.suvoda.com/products/ecoa.  

About Suvoda:
Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system, and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company’s Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and contract research organizations (CROs) to support more than 1,500 trials across more than 85 countries. To learn more, visit suvoda.com. Follow Suvoda on LinkedIn

CONTACT: marketing@suvoda.com

Logo – https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg

View original content:https://www.prnewswire.com/apac/news-releases/suvoda-awarded-us-patent-for-its-ecoa-software-architecture-302304690.html

SOURCE Suvoda LLC

Continue Reading

Technology

9Pay Presents All-in-One Efficient Financial Solution at Singapore FinTech Festival

Published

on

By

HANOI, Vietnam, Nov. 14, 2024 /PRNewswire/ — From November 6 to 8, 9Pay showcased comprehensive payment services in Vietnam to businesses at the Singapore FinTech Festival 2024. 9Pay’s participation at one of the largest global Fintech events has attracted significant attention from companies and industry experts.

Singapore FinTech Festival (SFF) 2024 is organized by the Monetary Authority of Singapore in collaboration with the Association of Banks in Singapore for the 9th time at the Singapore EXPO Convention & Exhibition Center. The event attracted 65,000 participants from 134 countries and regions, including more than 3,400 government and regulatory attendees across 665 central banks, regulatory institutions, and other government organizations.

For 9Pay, attending SFF 2024 in Singapore is a strategic step to strengthening its position in fintech in Southeast Asia and the world. Coming for the first time as an official exhibitor of this famous financial event, 9Pay was welcomed warmly by many financial professionals and clients, as a trusted fintech company in Vietnam. This has contributed to strengthening the position of Vietnam’s financial technology industry in the international area, demonstrating that Vietnamese fintech enterprises are ready to compete and integrate into regional and global marketplaces.

The State Bank of Vietnam’s 2024 report highlights Vietnam as a top FDI destination, ranking 25th globally and outpacing regional peers like Indonesia, the Philippines, and Thailand. Key drivers include Vietnam’s large domestic market, robust consumer spending, and proactive government reforms that streamline processes and bolster foreign trade. Improved technology infrastructure has made sectors like e-commerce, fintech, logistics, education, and tourism particularly attractive. With deep market insight, 9Pay, a licensed payment intermediary, has empowered numerous companies to thrive in Vietnam by offering seamless, all-in-one payment solutions.

As the leading payment service provider, 9Pay has established powerful partnerships with international PSPs and Remittances, allowing partners to receive payments seamlessly and facilitating smooth money transfers to Vietnamese beneficiaries. Typical instances include e-commerce platforms expanding in Vietnam that can easily collect payments and promote growth, and an online education provider that integrated 9Pay’s localized payment solution, simplifying tuition payments for Vietnamese students while improving user experience.

Boost Business Efficiency with Collection – Disbursement and Payment Gateway Service

The 9Pay Collection and Pay-Out Service offers several standout benefits for partners aiming to expand and operate efficiently in Vietnam. One of key strengths is the Localized Banking Advantage, enabling partners to use 9Pay as a local bank account for seamless collection and disbursement, simplifying operations and enhancing financial workflows.

Additionally, there are lots of new cross-border payment regulations this year. Companies need to thoroughly understand and strictly comply with these regulations to ensure legal and stable business operations. Expert Tax Advisory for smooth market entry of 9Pay will provide partners with crucial insights into their tax obligations, easing compliance and fostering confident growth in the Vietnamese market.

With a cost-efficient fee structure, 9Pay helps partners minimize transaction expenses, allowing for better cost management and increased profitability. The service also tackles the complexities of cross-border transactions through optimized FX rates and transparent fees, providing live exchange rates and clear pricing to ensure predictable, competitive costs and address currency fluctuation challenges.

Another significant advantage of 9Pay is its 24/7 dedicated support, offering reliable assistance even on weekends and holidays to promptly resolve issues and maintain smooth operations.

The leading fintech company in digital financial innovation and cross-border payments in Vietnam

Throughout the event, the 9Pay team had valuable individual meetings with decision-makers as well as took part in in-depth discussion sessions led by industry experts. With significant expertise regarding the future of the Fintech sector, including topics such as Next-Gen Transactions, Digital Assets, AI, and Quantum, 9Pay has new directions for its product development roadmap.

Furthermore, with many new cross-border payment rules this year, 9Pay is dedicated to giving professional help to educate businesses on regulatory requirements, best practices, and platform capabilities that ensure smooth, compliant transactions. For better guidance and support on payment solutions in Vietnam, businesses can connect with 9Pay experts here.

Building on its success at the SFF, 9Pay is set to advance Vietnam’s fintech sector globally by providing seamless, compliant, and cost-effective cross-border payment solutions. With a commitment to deepening APAC partnerships and adapting to evolving regulations, 9Pay empowers businesses to grow confidently in Vietnam and beyond, positioning itself as a leader in the future of global fintech.

 

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/9pay-presents-all-in-one-efficient-financial-solution-at-singapore-fintech-festival-302304265.html

SOURCE 9Pay JSC

Continue Reading

Trending